{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:54:30Z","timestamp":1781636070897,"version":"3.54.5"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Prostate-specific membrane antigen (PSMA) PET\/CT is recognized as the most accurate imaging modality for staging of patients with intermediate and high-risk prostate cancer (PCa). PSMA PET\/CT has also shown potential in the local (T) staging of primary PCa. The purpose of this study was to explore the value of quantitative PSMA PET\/CT parameters in addition to the standard visual assessment for local T-stage classification in a large single-center retrospective cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Sequential intermediate- and high-risk primary PCa patients who underwent staging PSMA PET\/CT prior to robot-assisted radical prostatectomy were included. Visual assessment of T-stage (miT-stage) was performed alongside quantitative analysis of PSMA PET\/CT parameters, including SUVmax, SUVpeak, tumor volume (PSMA-vol), total lesion PSMA expression (PSMA-TL), and tumor longest capsule contact (LCC). The pathological tumor stage derived from radical prostatectomy specimens served as the reference standard. Univariable and multivariable logistic regression analyses were performed to develop clinical risk models for predicting pT3-stage disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 223 evaluable patients with PSMA-positive primary PCa were included. Univariable analyses of individual imaging parameters yielded AUCs of 0.53\u20130.63 for pT3a, 0.64\u20130.74 for \u2265\u2009pT3b, and 0.59\u20130.69 for overall\u2009\u2265\u2009pT3-stage. In multivariable analyses, LCC was the sole independent predictor for pT3a stage; miT-stage, LCC, and PSMA-vol were independent predictors for \u2265\u2009pT3b-stage; and LCC together with PSMA-vol were independent predictors for overall\u2009\u2265\u2009pT3-stage. Clinical risk models incorporating these predictors achieved AUCs of 0.62 for pT3a, 0.79 for \u2265\u2009pT3b, and 0.70 for \u2265\u2009pT3-stage.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Quantitative parameters derived from PSMA PET\/CT scans provide additional diagnostic accuracy for detecting extraprostatic tumor extension, particularly for \u2265\u2009pT3b-stage disease, outperforming visual assessment (miT-stage) alone.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-025-07757-3","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T04:10:59Z","timestamp":1770955859000},"page":"4374-4385","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Addition of quantitative imaging parameters to visual analysis improves the accuracy of PSMA PET\/CT for the local staging of primary prostate cancer"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2028-9713","authenticated-orcid":false,"given":"Maarten L.","family":"Donswijk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosemarijn H.","family":"Ettema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurits","family":"Wondergem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zing","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henk G.","family":"van der Poel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela E.","family":"Oprea-Lager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9 N.","family":"Vis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,13]]},"reference":[{"key":"7757_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17\u201348. https:\/\/doi.org\/10.3322\/caac.21763.","journal-title":"CA Cancer J Clin"},{"key":"7757_CR2","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/s0140-6736(20)30314-7","volume":"395","author":"MS Hofman","year":"2020","unstructured":"Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395:1208\u201316. https:\/\/doi.org\/10.1016\/s0140-6736(20)30314-7.","journal-title":"Lancet"},{"key":"7757_CR3","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/jamaoncol.2019.0096","volume":"5","author":"WP Fendler","year":"2019","unstructured":"Fendler WP, Calais J, Eiber M, Flavell RR, Mishoe A, Feng FY, et al. Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial. JAMA Oncol. 2019;5:856\u201363. https:\/\/doi.org\/10.1001\/jamaoncol.2019.0096.","journal-title":"JAMA Oncol"},{"key":"7757_CR4","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","volume":"86","author":"P Cornford","year":"2024","unstructured":"Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer-2024 update. Part I: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2024;86:148\u201363. https:\/\/doi.org\/10.1016\/j.eururo.2024.03.027.","journal-title":"Eur Urol"},{"key":"7757_CR5","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1007\/s00259-024-06594-0","volume":"51","author":"ML Donswijk","year":"2024","unstructured":"Donswijk ML, Ettema RH, Meijer D, Wondergem M, Cheung Z, Bekers EM, et al. The accuracy and intra- and interobserver variability of PSMA PET\/CT for the local staging of primary prostate cancer. Eur J Nucl Med Mol Imaging. 2024;51:1741\u201352. https:\/\/doi.org\/10.1007\/s00259-024-06594-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7757_CR6","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1007\/s00259-021-05245-y","volume":"48","author":"F Ceci","year":"2021","unstructured":"Ceci F, Oprea-Lager DE, Emmett L, Adam JA, Bomanji J, Czernin J, et al. E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET. Eur J Nucl Med Mol Imaging. 2021;48:1626\u201338. https:\/\/doi.org\/10.1007\/s00259-021-05245-y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7757_CR7","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2967\/jnumed.117.198119","volume":"59","author":"M Eiber","year":"2018","unstructured":"Eiber M, Herrmann K, Calais J, Hadaschik B, Giesel FL, Hartenbach M, et al. Prostate cancer molecular imaging standardized evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET\/CT. J Nucl Med. 2018;59:469\u201378. https:\/\/doi.org\/10.2967\/jnumed.117.198119.","journal-title":"J Nucl Med"},{"key":"7757_CR8","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.eururo.2023.02.002","volume":"83","author":"R Seifert","year":"2023","unstructured":"Seifert R, Emmett L, Rowe SP, Herrmann K, Hadaschik B, Calais J, et al. Second version of the prostate cancer molecular imaging standardized evaluation framework including response evaluation for clinical trials (PROMISE V2). Eur Urol. 2023;83:405\u201312. https:\/\/doi.org\/10.1016\/j.eururo.2023.02.002.","journal-title":"Eur Urol"},{"key":"7757_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s13244-022-01217-4","volume":"13","author":"R Laudicella","year":"2022","unstructured":"Laudicella R, Skawran S, Ferraro DA, Muhlematter UJ, Maurer A, Grunig H, et al. Quantitative imaging parameters to predict the local staging of prostate cancer in intermediate- to high-risk patients. Insights Imaging. 2022;13:75. https:\/\/doi.org\/10.1186\/s13244-022-01217-4.","journal-title":"Insights Imaging"},{"key":"7757_CR10","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1007\/s00259-017-3670-z","volume":"44","author":"WP Fendler","year":"2017","unstructured":"Fendler WP, Eiber M, Beheshti M, Bomanji J, Ceci F, Cho S, et al. 68Ga-PSMA PET\/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2017;44:1014\u201324. https:\/\/doi.org\/10.1007\/s00259-017-3670-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7757_CR11","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1007\/s00259-022-06089-w","volume":"50","author":"WP Fendler","year":"2023","unstructured":"Fendler WP, Eiber M, Beheshti M, Bomanji J, Calais J, Ceci F, et al. PSMA PET\/CT: joint EANM procedure guideline\/SNMMI procedure standard for prostate cancer imaging 2.0. Eur J Nucl Med Mol Imaging. 2023;50:1466\u201386. https:\/\/doi.org\/10.1007\/s00259-022-06089-w.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7757_CR12","unstructured":"Intellispace Portal. Eindhoven, the Netherlands: Philips Healthcare."},{"issue":"Suppl 1","key":"7757_CR13","doi-asserted-by":"publisher","first-page":"S122","DOI":"10.2967\/jnumed.108.057307","volume":"50","author":"RL Wahl","year":"2009","unstructured":"Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(Suppl 1):S122\u201350. https:\/\/doi.org\/10.2967\/jnumed.108.057307.","journal-title":"J Nucl Med"},{"key":"7757_CR14","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.eururo.2021.08.002","volume":"80","author":"L Emmett","year":"2021","unstructured":"Emmett L, Buteau J, Papa N, Moon D, Thompson J, Roberts MJ, et al. The additive diagnostic value of prostate-specific membrane antigen positron emission tomography computed tomography to multiparametric magnetic resonance imaging triage in the diagnosis of prostate cancer (PRIMARY): a prospective multicentre study. Eur Urol. 2021;80:682\u20139. https:\/\/doi.org\/10.1016\/j.eururo.2021.08.002.","journal-title":"Eur Urol"},{"key":"7757_CR15","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1111\/1754-9485.13084","volume":"64","author":"D Brauchli","year":"2020","unstructured":"Brauchli D, Singh D, Chabert C, Somasundaram A, Collie L. Tumour-capsule interface measured on 18F-DCFPyL PSMA positron emission tomography\/CT imaging comparable to multi-parametric MRI in predicting extra-prostatic extension of prostate cancer at initial staging. J Med Imaging Radiat Oncol. 2020;64:829\u201338. https:\/\/doi.org\/10.1111\/1754-9485.13084.","journal-title":"J Med Imaging Radiat Oncol"},{"key":"7757_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s41824-024-00234-4","volume":"9","author":"E Hvittfeldt","year":"2025","unstructured":"Hvittfeldt E, Hedeer F, Thimansson E, Sandeman K, Minarik D, Ingvar J, et al. Semi-standardized evaluation of extraprostatic extension and seminal vesicle invasion with [(18)F]PSMA-1007 PET\/CT: a comparison to MRI using histopathology as reference. EJNMMI Rep. 2025;9:1. https:\/\/doi.org\/10.1186\/s41824-024-00234-4.","journal-title":"EJNMMI Rep"},{"key":"7757_CR17","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/PAS.0000000000000530","volume":"40","author":"JI Epstein","year":"2016","unstructured":"Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA. The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol. 2016;40:244\u201352. https:\/\/doi.org\/10.1097\/PAS.0000000000000530.","journal-title":"Am J Surg Pathol"},{"key":"7757_CR18","volume-title":"TNM Classification of Malignant Tumours, 8th edition","author":"J Brierly","year":"2017","unstructured":"Brierly J. TNM Classification of Malignant Tumours, 8th edition. Wiley-Blackwell; 2017."},{"key":"7757_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s41824-020-00085-9","volume":"4","author":"S Woo","year":"2020","unstructured":"Woo S, Ghafoor S, Becker AS, Han S, Wibmer AG, Hricak H, et al. Prostate-specific membrane antigen positron emission tomography (PSMA-PET) for local staging of prostate cancer: a systematic review and meta-analysis. Eur J Hybrid Imaging. 2020;4:16. https:\/\/doi.org\/10.1186\/s41824-020-00085-9.","journal-title":"Eur J Hybrid Imaging"},{"key":"7757_CR20","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1007\/s13139-017-0476-7","volume":"51","author":"CJ von Klot","year":"2017","unstructured":"von Klot CJ, Merseburger AS, Boker A, Schmuck S, Ross TL, Bengel FM. <article-title update=\"added\">68Ga-PSMA PET\/CT imaging predicting intraprostatic tumor extent, extracapsular extension and seminal vesicle invasion prior to radical prostatectomy in patients with prostate cancer. Nucl Med Mol Imaging. 2017;51:314\u201322. https:\/\/doi.org\/10.1007\/s13139-017-0476-7.","journal-title":"Nucl Med Mol Imaging"},{"key":"7757_CR21","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1002\/pros.23812","volume":"79","author":"B Yilmaz","year":"2019","unstructured":"Yilmaz B, Turkay R, Colakoglu Y, Baytekin HF, Ergul N, Sahin S, et al. Comparison of preoperative locoregional Ga-68 PSMA-11 PET-CT and mp-MRI results with postoperative histopathology of prostate cancer. Prostate. 2019;79:1007\u201317. https:\/\/doi.org\/10.1002\/pros.23812.","journal-title":"Prostate"},{"key":"7757_CR22","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1111\/bju.16608","volume":"135","author":"DC Chen","year":"2025","unstructured":"Chen DC, Huang S, Papa N, Siva S, Bolton DM, Lawrentschuk N, et al. Impact of intraprostatic PSMA maximum standardised uptake value following prostatectomy: a systematic review and meta-analysis. BJU Int. 2025;135:720\u201332. https:\/\/doi.org\/10.1111\/bju.16608.","journal-title":"BJU Int"},{"key":"7757_CR23","doi-asserted-by":"publisher","DOI":"10.1007\/s00261-025-04948-2","author":"S Woo","year":"2025","unstructured":"Woo S, Freedman D, Becker AS, Leithner D, Charbel C, Mayerhoefer ME, et al. Evaluating extraprostatic extension of prostate cancer: pragmatic integration of MRI and PSMA-PET\/CT. Abdom Radiol (NY). 2025. https:\/\/doi.org\/10.1007\/s00261-025-04948-2.","journal-title":"Abdom Radiol (NY)"},{"key":"7757_CR24","doi-asserted-by":"publisher","first-page":"684","DOI":"10.3348\/kjr.2019.0842","volume":"21","author":"TH Kim","year":"2020","unstructured":"Kim TH, Woo S, Han S, Suh CH, Ghafoor S, Hricak H, et al. The diagnostic performance of the length of tumor capsular contact on MRI for detecting prostate cancer extraprostatic extension: a systematic review and meta-analysis. Korean J Radiol. 2020;21:684\u201394. https:\/\/doi.org\/10.3348\/kjr.2019.0842.","journal-title":"Korean J Radiol"},{"key":"7757_CR25","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-025-07455-0","author":"V Sweere","year":"2025","unstructured":"Sweere V, Slot AB, Hermsen R, Heetman JG, Wever L, Lavalaye J, et al. Prognostic value of PSMA PET\/CT-Based local staging in predicting biochemical recurrence after radical prostatectomy. Eur J Nucl Med Mol Imaging. 2025. https:\/\/doi.org\/10.1007\/s00259-025-07455-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7757_CR26","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.eururo.2015.07.029","volume":"70","author":"M de Rooij","year":"2016","unstructured":"de Rooij M, Hamoen EH, Witjes JA, Barentsz JO, Rovers MM. Accuracy of magnetic resonance imaging for local staging of prostate cancer: a diagnostic meta-analysis. Eur Urol. 2016;70:233\u201345. https:\/\/doi.org\/10.1016\/j.eururo.2015.07.029.","journal-title":"Eur Urol"},{"key":"7757_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2024.11.002","author":"TFW Soeterik","year":"2024","unstructured":"Soeterik TFW, Heetman JG, Hermsen R, Wever L, Lavalaye J, Vinken M, et al. The added value of prostate-specific membrane antigen positron emission tomography\/Computed tomography to magnetic resonance imaging for local staging of prostate cancer in patients undergoing radical prostatectomy. Eur Urol Oncol. 2024. https:\/\/doi.org\/10.1016\/j.euo.2024.11.002.","journal-title":"Eur Urol Oncol"}],"updated-by":[{"DOI":"10.1007\/s00259-026-07861-y","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000}}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07757-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07757-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07757-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:12:27Z","timestamp":1781633547000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07757-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,13]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["7757"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07757-3","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,13]]},"assertion":[{"value":"13 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: The authors regret that the version of Tables 3, 6 and 7 that appeared in the original published article are incorrect. The correct and incorrect version of Tables 3, 6 and 7 are shown in the erratum article. The original article has been corrected.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00259-026-07861-y","URL":"https:\/\/doi.org\/10.1007\/s00259-026-07861-y","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Institutional review board approval was obtained from both hospitals (AUMC and NCI-AVL) with a waiver for informed consent (VUmc2019.586 and IRBd20-041).All methods were carried out in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}